Assessment of radiation doses and DNA damage in pediatric patients undergoing interventional procedures for vascular anomalies

Mutat Res Genet Toxicol Environ Mutagen. 2023 Jul:889:503653. doi: 10.1016/j.mrgentox.2023.503653. Epub 2023 Jun 24.

Abstract

Interventional procedures (IPs) have been widely used to treat vascular anomalies (VA) in recent years. However, patients are exposed to low-dose X-ray ionizing radiation (IR) during these fluoroscopy-guided IPs. We collected clinical information and IR doses during IPs and measured biomarkers including γ-H2AX, chromosome aberrations (CA), and micronuclei (MN), which underpin radiation-induced DNA damage, from 74 pediatric patients before and after IPs. For the 74 children, the range of dose-area product (DAP) values was from 1.2 to 1754.6 Gy∙cm2, with a median value of 27.1 Gy∙cm2. DAP values were significantly higher in children with lesions in the head and neck than in the limbs and trunk; the age and weight of children revealed a strong positive correlation with DAP values. The treated patients as a group demonstrated an increase in all three endpoints relative to baseline following IPs. Children with vascular tumors have a higher risk of dicentric chromosome + centric ring (dic+r) and cytokinesis-block micronucleus (CBMN) after IPs than children with vascular malformations. The younger the patient, the greater the risk of CA after IPs. Moreover, rogue cells (RCs) were found in five children (approximately 10%) after IPs, and the rates of dic+r and CBMN were significantly higher than those of other children (Z = -3.576, p < 0.001). These results suggest that there may be some children with VA who are particularly sensitive to IR, but more data and more in-depth experiments will be needed to verify this in the future.

Keywords: Chromosomal aberrations; Interventional procedures; Low dose radiation effects; Micronuclei; Vascular anomalies; γ-H2AX.

MeSH terms

  • Cell Nucleus
  • Child
  • Chromosome Aberrations*
  • DNA Damage
  • Humans
  • Radiation Dosage
  • Vascular Malformations*